These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer. Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327 [TBL] [Abstract][Full Text] [Related]
4. Chapter four--Design of improved oncolytic adenoviruses. Alemany R Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243 [TBL] [Abstract][Full Text] [Related]
5. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Wold WS; Toth K Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in oncolytic adenovirus therapies for cancer. Rosewell Shaw A; Suzuki M Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in genetic modification of adenovirus vectors for cancer treatment. Yamamoto Y; Nagasato M; Yoshida T; Aoki K Cancer Sci; 2017 May; 108(5):831-837. PubMed ID: 28266780 [TBL] [Abstract][Full Text] [Related]
8. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Li HJ; Everts M; Yamamoto M; Curiel DT; Herschman HR Cancer Res; 2009 Jan; 69(2):554-64. PubMed ID: 19147569 [TBL] [Abstract][Full Text] [Related]
9. Construction of targeted and armed oncolytic adenoviruses. Doronin K; Shayakhmetov DM Methods Mol Biol; 2012; 797():35-52. PubMed ID: 21948467 [TBL] [Abstract][Full Text] [Related]
11. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents? Bots STF; Hoeben RC Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650405 [TBL] [Abstract][Full Text] [Related]
12. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Cerullo V; Koski A; Vähä-Koskela M; Hemminki A Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247 [TBL] [Abstract][Full Text] [Related]
13. Concepts in Oncolytic Adenovirus Therapy. Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863 [TBL] [Abstract][Full Text] [Related]
14. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
19. Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy. Ran L; Tan X; Li Y; Zhang H; Ma R; Ji T; Dong W; Tong T; Liu Y; Chen D; Yin X; Liang X; Tang K; Ma J; Zhang Y; Cao X; Hu Z; Qin X; Huang B Biomaterials; 2016 May; 89():56-66. PubMed ID: 26950165 [TBL] [Abstract][Full Text] [Related]
20. Modification of oncolytic adenovirus and its application in cancer therapy. Liang Y; He J; Zhao Y Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]